Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw unusually-strong trading volume on Friday . Approximately 4,097 shares traded hands during mid-day trading, an increase of 28% from the previous session’s volume of 3,212 shares.The stock last traded at $23.8490 and had previously closed at $22.34.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AAPG. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a report on Friday. They set a “buy” rating and a $40.00 price target for the company. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. BTIG Research restated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. Finally, Rodman & Renshaw initiated coverage on Ascentage Pharma Group International in a research note on Tuesday, January 13th. They issued a “buy” rating and a $48.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The company has a 50 day moving average price of $24.43 and a 200 day moving average price of $27.97.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million for the quarter. As a group, analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Large investors have recently modified their holdings of the stock. UBS Group AG grew its stake in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. XY Capital Ltd raised its stake in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International during the second quarter valued at approximately $391,000. Citadel Advisors LLC bought a new position in Ascentage Pharma Group International during the 3rd quarter worth approximately $383,000. Finally, ABC Arbitrage SA bought a new position in Ascentage Pharma Group International during the 3rd quarter worth approximately $204,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.